Histogenics Corporation Announces Pricing of Underwritten Registered Direct Offering of 2,340,430 Shares of Common Stock

Biotech Investing

Histogenics (Nasdaq:HSGX), a leader in the development of restorative cell therapies, today announced the pricing of an underwritten registered direct offering of 2,340,430 shares of its common stock at a price of $2.35 per share. As quoted in the press release: The gross proceeds to Histogenics from this offering are expected to be $5,500,010.50, before …

The gross proceeds to Histogenics from this offering are expected to be $5,500,010.50, before deducting underwriting discounts and commissions, and offering expenses payable by Histogenics. Certain entities affiliated with directors of Histogenics may purchase shares of common stock in the offering at $2.56, today’s closing price of our common stock on The Nasdaq Capital Market.
Histogenics intends to use the net proceeds from the offering for working capital and general corporate purposes.

Click here to read the full press release.

net proceeds Biotech Investing